CAD 0.03
(0.0%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 65.2 Thousand CAD | 45.39% |
2022 | 44.84 Thousand CAD | -80.5% |
2021 | 229.97 Thousand CAD | -38.95% |
2020 | 376.73 Thousand CAD | 18.87% |
2019 | 316.91 Thousand CAD | 194.95% |
2018 | 107.44 Thousand CAD | 0.0% |
2017 | - CAD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | 281.00 CAD | -94.29% |
2024 Q2 | 825.00 CAD | 193.59% |
2023 Q2 | 17.68 Thousand CAD | 153.01% |
2023 Q4 | 4921.00 CAD | -86.77% |
2023 FY | 65.2 Thousand CAD | 45.39% |
2023 Q3 | 37.19 Thousand CAD | 110.3% |
2023 Q1 | 6991.00 CAD | 139.62% |
2022 Q2 | 12.81 Thousand CAD | -57.27% |
2022 Q4 | -17.64 Thousand CAD | -189.63% |
2022 Q3 | 19.68 Thousand CAD | 53.62% |
2022 Q1 | 29.98 Thousand CAD | -21.94% |
2022 FY | 44.84 Thousand CAD | -80.5% |
2021 Q4 | 38.41 Thousand CAD | -31.15% |
2021 FY | 229.97 Thousand CAD | -38.95% |
2021 Q2 | 70.64 Thousand CAD | 8.47% |
2021 Q1 | 65.12 Thousand CAD | -47.64% |
2021 Q3 | 55.79 Thousand CAD | -21.01% |
2020 Q3 | 98.97 Thousand CAD | 8.16% |
2020 Q2 | 91.5 Thousand CAD | 47.9% |
2020 Q1 | 61.86 Thousand CAD | -25.62% |
2020 FY | 376.73 Thousand CAD | 18.87% |
2020 Q4 | 124.39 Thousand CAD | 25.68% |
2019 Q3 | 120.31 Thousand CAD | 81.99% |
2019 Q4 | 83.17 Thousand CAD | -30.87% |
2019 FY | 316.91 Thousand CAD | 194.95% |
2019 Q2 | 66.11 Thousand CAD | 39.73% |
2019 Q1 | 47.31 Thousand CAD | 5.45% |
2018 Q2 | 25.24 Thousand CAD | 84033.33% |
2018 FY | 107.44 Thousand CAD | 0.0% |
2018 Q4 | 44.86 Thousand CAD | 20.26% |
2018 Q3 | 37.3 Thousand CAD | 47.82% |
2018 Q1 | 30.00 CAD | 0.0% |
2017 FY | - CAD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
AI/ML Innovations Inc. | 294.86 Thousand CAD | 77.888% |
Diagnamed Holdings Corp. | - CAD | -Infinity% |
Pangenomic Health Inc. | -681.43 Thousand CAD | 109.568% |
Treatment.Com International Inc. | - CAD | -Infinity% |
Unidoc Health Corp. | -68.26 Thousand CAD | 195.516% |